ANN-LII CHENGKang Y.-K.Chen Z.Tsao C.-J.Qin S.Kim J.S.Luo R.Feng J.Ye S.Yang T.-S.Xu J.Sun Y.Liang H.Liu J.Wang J.Tak W.Y.Pan H.Burock K.Zou J.Voliotis D.Guan Z.2021-09-012021-09-012009https://www.scopus.com/inward/record.uri?eid=2-s2.0-57749189578&doi=10.1016%2fS1470-2045%2808%2970285-7&partnerID=40&md5=03a2787bcaaed09328feb4aec2398a97https://scholars.lib.ntu.edu.tw/handle/123456789/580332[SDGs]SDG3placebo; sorafenib; adult; advanced cancer; aged; alopecia; anorexia; article; ascites; Asia; China; clinical trial; controlled clinical trial; controlled study; desquamation; diarrhea; disease control; disease course; double blind procedure; drug dose reduction; drug efficacy; drug safety; drug tolerability; drug withdrawal; fatigue; female; hand foot syndrome; human; hypertension; interactive voice response system; liver cell carcinoma; liver dysfunction; liver function; major clinical study; male; medical decision making; multicenter study; multiple cycle treatment; nausea; outcome assessment; overall survival; phase 3 clinical trial; priority journal; randomized controlled trial; rash; South Korea; Taiwan; treatment outcome; upper gastrointestinal bleeding; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyridinesjournal article10.1016/S1470-2045(08)70285-7190954972-s2.0-57749189578